Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy

Rohrbach, Janine; Robinson, Nicola; Harcourt, Gillian; Hammond, Emma; Gaudieri, Silvana; Gorgievski, Meri; Telenti, Amalio; Keiser, Olivia; Günthard, Huldrych F; Hirschel, Bernhard; Hoffmann, Matthias; Bernasconi, Enos; Battegay, Manuel; Furrer, Hansjakob; Klenerman, Paul; Rauch, Andri (2010). Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 59(9), pp. 1252-1258. London: BMJ Publishing Group 10.1136/gut.2009.205971

[img] Text
Rohrbach Gut 2010.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (308kB) | Request a copy

Background Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels. Aims To investigate whether long-term combination antiretroviral therapy (cART) restores HCV-specific T cell responses and improves the control of HCV replication. Methods T cell responses were evaluated longitudinally in 80 HIV/HCV coinfected individuals by ex vivo interferon-γ-ELISpot responses to HCV core peptides, that predominantly stimulate CD4+ T cells. HCV RNA levels were assessed by real-time PCR in 114 individuals. Results The proportion of individuals with detectable T cell responses to HCV core peptides was 19% before starting cART, 24% in the first year on cART and increased significantly to 45% and 49% after 33 and 70 months on cART (p=0.001). HCV-specific immune responses increased in individuals with chronic (+31%) and spontaneously cleared HCV infection (+30%). Median HCV RNA levels before starting cART were 6.5 log10 IU/ml. During long-term cART, median HCV-RNA levels slightly decreased compared to pre-cART levels (−0.3 log10 IU/ml, p=0.02). Conclusions Successful cART is associated with increasing cellular immune responses to HCV core peptides and with a slight long-term decrease in HCV RNA levels. These findings are in line with the favourable clinical effects of cART on the natural history of hepatitis C and with the current recommendation to start cART earlier in HCV/HIV coinfected individuals.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Keiser, Olivia; Furrer, Hansjakob and Rauch, Andri

ISSN:

0017-5749

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

11 Sep 2017 19:14

Publisher DOI:

10.1136/gut.2009.205971

PubMed ID:

20660698

Web of Science ID:

000282187100020

BORIS DOI:

10.7892/boris.1161

URI:

https://boris.unibe.ch/id/eprint/1161 (FactScience: 202017)

Actions (login required)

Edit item Edit item
Provide Feedback